Immunotherapy for glioma: Current management and future application

Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved limited improvements in the prognosis of glioma patients. Immunotherapy, a revolution in cancer treatment, has become a promisi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters Vol. 476; pp. 1 - 12
Main Authors: Xu, Shengchao, Tang, Lu, Li, Xizhe, Fan, Fan, Liu, Zhixiong
Format: Journal Article
Language:English
Published: Ireland Elsevier B.V 28.04.2020
Elsevier Limited
Subjects:
Antibodies
Apoptosis
Blood-brain barrier
Brain cancer
Brain Neoplasms - immunology
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Brain tumors
Cancer therapies
Central nervous system
Checkpoint
Chemotherapy
Clinical trials
Cytotoxicity
Disease Management
FDA approval
Glioma
Glioma - immunology
Glioma - pathology
Glioma - therapy
Humans
Immunotherapy
Immunotherapy - methods
Ligands
Medical prognosis
Medical research
Melanoma
Oncolytic virus
Progenitor cells
Prognosis
Radiation therapy
Stem cells
Surgery
Tumors
Vaccine
Vascular endothelial growth factor
Checkpoint
Vaccine
Oncolytic virus
Glioma
Immunotherapy
ISSN:0304-3835, 1872-7980, 1872-7980
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved limited improvements in the prognosis of glioma patients. Immunotherapy, a revolution in cancer treatment, has become a promising strategy with the ability to penetrate the blood-brain barrier since the pioneering discovery of lymphatics in the central nervous system. Here we detail the current management of gliomas and previous studies assessing different immunotherapies in gliomas, despite the fact that the associated clinical trials have not been completed yet. Moreover, several drugs that have undergone clinical trials are listed as novel strategies for future application; however, these clinical trials have indicated limited efficacy in glioma. Therefore, additional studies are warranted to evaluate novel therapeutic approaches in glioma treatment. •Current management of glioma is limited and cannot reach an optimal remission.•Immune checkpoint inhibitors and CAR-T therapy exhibit promising therapeutic activities as immunotherapies.•Combination of oncolytic virus, dendritic vaccines, and immune checkpoint inhibitors has synergistic effect killing tumors.•Novel CAR-T strategies and bi-specific antibodies are developed in cancer treatment.•Combination and personalized therapy take a crucial place in future application.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0304-3835
1872-7980
1872-7980
DOI:10.1016/j.canlet.2020.02.002